XML 46 R32.htm IDEA: XBRL DOCUMENT v3.24.1
Shareholders' Equity (Tables)
 12 Months Ended
Dec. 31, 2023
Stockholders' Equity Note [Abstract]  
Schedule of Stock Options Stock options for the year ended December 31, 2023 under the Company’s plans are as follows:
   Number of
options		   Weighted
average
exercise
price		   Weighted
average
remaining
contractual
term
(in years)		   Aggregate
intrinsic
value		 
                 
Outstanding as of January 1, 2023   40,006    8.02    2.77    117 
Granted   -    -           
Exercised   -    -           
Expired and forfeited   (409)   10.99           
Outstanding as of December 31, 2023   39,597    7.98    1.75    16 
Vested and expected to vest at December 31, 2023   39,597    7.98    1.75    16 
Exercisable as of December 31, 2023   39,597    7.98    1.75    16 
Schedule of RSUs under the Company’s 2013 Share Option Plan RSUs for the year ended December 31, 2023 under the Company’s 2013 Share Option Plan and 2023 Equity Incentive Plan are as follows:
   Number of
RSUs		   Weighted
average
remaining
contractual
term
(in years)		   Aggregate
intrinsic
value		 
             
Outstanding as of January 1, 2023   780,697    1.53   $8,541 
Granted   1,198,500           
Vested   (568,650)          
Cancelled   (90,017)          
Outstanding as of December 31, 2023   1,320,530    1.51   $10,643 
Schedule of Department Allocation of Share-Based Compensation Charges The following table summarizes the allocation of the Company’s share-based compensation within the statements of operations:
   Year ended December 31, 
   2023   2022   2021 
             
Cost of revenues  $440   $391   $207 
Research and development, net   2,690    2,503    1,368 
Sales and marketing   1,819    1,386    865 
General and administrative   1,168    894    916 
   $6,117   $5,174   $3,356